PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: inGenious Targeting Laboratory, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

inGenious Targeting Laboratory Scores Contracts for Use of Innovative TruHumanization™ Technology - inGenious Targeting Laboratory, a leading global provider of genetically modified mouse models, announced today that they have solidified multiple contracts to create mouse models using their exclusive TruHumanization™ technology
inGenious Targeting Laboratory Scores Contracts for Use of Innovative TruHumanization™ Technology

 

NewswireToday - /newswire/ - Ronkonkoma, NY, United States, 2014/08/20 - inGenious Targeting Laboratory, a leading global provider of genetically modified mouse models, announced today that they have solidified multiple contracts to create mouse models using their exclusive TruHumanization™ technology.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

TruHumanization™ technology by inGenious has generated much interest from a variety of companies and institutes. These contracts come just two weeks after the release of this innovative technology platform.
As the recent spike in translational research continues, there has been an increased need for animal models that better mimic phenotypes seen in humans. Traditional methods of creating humanized mouse models manipulate only the coding regions of the genes of interest, and therefore are limited in their true representation of human gene function. The Company’s exclusive TruHumanization™ technology offers a solution to the challenges presented by standard methods to humanize the mouse. This technology utilizes large BACs, enabling inGenious to replace the entire mouse gene with the entire human gene sequence including promoter, intron, exon, and regulatory sequences. This leads to more faithful gene regulation and processing as well as the potential to perform functional and regulatory studies on multiple transcripts.

President Paul J. Sheiffele believes this technology will provide scientists with more accurate models for studying human disease, setting inGenious Targeting Laboratory apart from other mouse model companies.

About inGenious Targeting Laboratory

Established in 1998, inGenious Targeting Laboratory (iTL) exclusively creates mice whose genetic make-up is tailored to the client’s research needs. Clients retain all intellectual property rights to their projects. A full range of project capabilities are available including: conventional and conditional knockouts, knockin models (humanized, inducible, reporter gene/cassette insertion, point mutations), as well as novel approaches for generating customized mouse models. Projects are initiated immediately upon completion of design parameters and progress to completion on-site in the USA, under the supervision of a dedicated scientific Project Manager. iTL is located in Ronkonkoma, New York.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: inGenious Targeting Laboratory, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


inGenious Targeting Laboratory Scores Contracts for Use of Innovative TruHumanization™ Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Tegan Ryan - GeneTargeting.com 
631-681-5653 inquiry[.]genetargeting.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any inGenious Targeting Laboratory, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From inGenious Targeting Laboratory, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)